TNBC accounts for approximately 10-20% of all cases of breast cancer and is characterized by the absence of yet defined molecular targets, including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [4, 5]. The gene discussed is ESR1; the disease is breast cancer.